CD19 and lymphoblastic lymphoma: In a clinical study, authors assessed the treatment outcome of kids and youthful adults with relapsed/refractory CD19+ ALL/lymphoblastic lymphoma treated on 5 CD19‐directed CAR T‐cell (CTL019 or humanized CART19) clinical trials or with commercial tisagenlecleucel.